MaxCyte is a global life sciences company applying its proprietary cell engineering technology platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte has placed its cutting-edge Flow Electroporation® Technology instruments worldwide, with all of the top ten global biopharmaceuticals, and has 70+ partnered program licenses in cell therapy including 35+ licensed for clinical use. MaxCyte helps its partners to unlock the full potential of their products.
Applied BioMath applies mechanistic modeling to drug R&D to help biotechnology and pharmaceutical companies answer complex, scientific questions and make critical decisions for the advancement of drug candidates. A team of mathematicians, biologists, clinical pharmacologists and pharmaceutical industry experts, they leverage biology, mathematics, proprietary technologies, HPC, and industry experience to perform massive scale simulations which enable groups to determine best-in-class properties of a clinical candidate, reduce attrition rates, and identify key differentiators from competitors.
AbSci is a global leader and innovator of revolutionary biomanufacturing technologies, designing and programming cells for next-generation biopharmaceuticals. AbSci's Protein Printing™ technology is the new gold standard in protein production, as it increases discovery throughput, accelerates development, reduces manufacturing costs, and increases plant capacity for the biopharmaceutical industry. Its patented SoluPro™ expression platform rapidly produces complex proteins, ranging from mAbs, Fabs, enzymes, hormones and peptides, to emerging novel classes of biotherapeutics. For more information, please visit https://www.absci.com.
Aracari Biosciences' propriety human Vascularized Micro-Organ (VMO) technology is the first to grow living, perfusable, human blood vessels within a microfluidic 3D platform. Growth of microtumors in these networks recapitulates the physiological delivery of nutrients, drug compounds, or immune cells through living blood vessels, providing a powerful tool for oncology and immune-oncology applications. At Aracari we collaborate with pharmaceutical clients to more accurately and efficiently test drug compounds to de-risk costly preclinical and clinical failures.
Elstar Therapeutics is fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating antibody-based, multi-functional therapeutics. Armed with a unique approach to engaging multiple immune mechanisms, we enable patients to harness their own body to fight cancer.Our Universal Targeted Immunotherapy (UniTI™) platform positions us to overcome barriers that have limited the full potential of other promising immunotherapeutic approaches.
Beacon Targeted Therapies
Beacon Targeted Therapies, a competitive and research intelligence database solution designed in partnership with pharmaceutical professionals across the world working in targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development. Find out more on how we can help you by visiting: